cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Abbreviated new drug application for antitumor cancer drug granted by U.S. FDA
December 14th, 2004
SuperGen, Inc. (SUPG) has received approval from the U.S. Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Paclitaxel Injection, 6 mg/mL, packaged in 30 mg/5 mL and 100 mg/16.7 mL multiple-dose vials. Paclitaxel belongs to the group of medicines called antineoplastics. The drug is equivalent to Bristol-Myers Squibb's Taxol Injection, an antitumor agent that has become one of the most widely used anti-cancer products. Paclitaxel Injection's approved indication is identical to Taxol and is indicated as treatment for a variety of cancers. Based in Dublin, California, SuperGen is a pharmaceutical...
Source: cancer weekly (2004-12-14)
|
